Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Prescription and cost of the studied drugs at 1, 6, and 18 months after the intervention

From: Effectiveness of educational outreach visits compared with usual guideline dissemination to improve family physician prescribing—an 18-month open cluster-randomized trial

  Intervention (n = 120) Control (n = 119) p
Omeprazole, % (95%CI)*
 + 1 month 46.86 (44.34–49.39) 47.36 (44.81–49.91) 0.744
 + 6 months 48.02 (45.58–50.46) 47.90 (45.01–50.79) 0.696
 + 18 months (primary outcome) 46.28 (43.77–48.79) 47.15 (44.39–49.91) 0.971
COX-2 inhibitors, % (95%CI)
 + 1 month 11.70 (9.83–13.57) 15.38 (12.87–17.90) 0.131
 + 6 months 11.59 (9.28–13.89) 15.74 (13.42–18.05) 0.061
 + 18 months (primary outcome) 12.07 (9.75–14.41) 13.08 (10.75–15.41) 0.085
Clopidogrel, DDD/1000 (95%CI)
 + 1 month 0.098 (0.886–0.107) 0.103 (0.094–0.112) 0.456
 + 6 months 0.090 (0.082–0.098) 0.099 (0.089–0.108) 0.230
 + 18 months 0.091 (0.083–0.100) 0.091 (0.082–0.100) 0.840
Cost 1–18 m/1000, € (95%CI)
 Gastric secretion modifiers 1647.79 (1541.37–1754.21) 1626.38 (1511.76–1741.01) 0.880
 NSAIDs 1099.26 (984.70–1213.81) 983.02 (873.49–1092.55) 0.515
 Clopidogrel 476.45 (428.34–524.57) 539.05 (491.22–586.87) 0.184
 Total 3223.50 (2999.55–3447.44) 3143.92 (2917.61–3370.23) 0.848
  1. DDD defined daily dose, CI confidence interval
  2. *Intervention intended to increase this proportion
  3. Intervention intended to decrease this proportion/absolute value